Beyond Efficacy: Persistence, NEDA, and Therapeutic Decision-Making in First-Line Multiple Sclerosis Treatment
In real-world practice, oral therapies tend to be associated with better long-term persistence than injectables, while effectiveness measured by cumulative NEDA-3 remains comparable. These findings highlight the role of patient-centered factors such as tolerability and administration route in treatment adherence, supporting cumulative NEDA as a meaningful outcome in clinical decision-making.
Authors
- César Sánchez-Franco
- Inés González‐Suarez (ORCID: https://orcid.org/0000-0002-9897-0771)
- María José Pérez-Haro (ORCID: https://orcid.org/0000-0001-8837-7643)
- Marta Aguado-Valcárcel
- Marta Torrente-Carballido
- Clara Helena López-Caneda (ORCID: https://orcid.org/0000-0001-7682-6464)
- María Marcos-Bobillo
- Elena Álvarez (ORCID: https://orcid.org/0000-0003-2687-7532)
- Sergio Antón-Fuente
Institutions
- Universidade de Santiago de Compostela (ES)
- University Hospital Complex Of Vigo (ES)
- Centro de Supercomputación de Galicia (ES)
- Galicia Sur Biomedical Foundation (ES)
- Complejo Hospitalario de Pontevedra (ES)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1007/s40120-025-00811-0
- Citations
- 1
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47